Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

about

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

Item

http://www.wikidata.org/entity/Q48027127

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@en

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@nl

type

Item

label

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@en

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@nl

prefLabel

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@en

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@nl

P1476

Circulating fibroblast growth factor 21 in patients with liver cirrhosis.

@en

P2093

Elisabeth M Haberl

http://www.w3.org/2001/XMLSchema#string

Lisa Rein-Fischboeck

http://www.w3.org/2001/XMLSchema#string

Rebekka Pohl

http://www.w3.org/2001/XMLSchema#string

Reiner Wiest

http://www.w3.org/2001/XMLSchema#string

Sabrina Krautbauer

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

Insulin resistance in clinical and experimental alcoholic liver disease

Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese

Bioanalytical advances in assays for C-reactive protein.

Fibroblast growth factor (Fgf) 21 is a novel target gene of the aryl hydrocarbon receptor (AhR).

The transhepatic endotoxin gradient is present despite liver cirrhosis and is attenuated after transjugular portosystemic shunt (TIPS).

Impact of serum chemerin levels on liver functional reserves and platelet counts in patients with hepatocellular carcinoma.

Study of adiponectin in chronic liver disease and cholestasis.

Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies.

Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress

P2888

s10238-017-0468-z

P304

63-69

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S10238-017-0468-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Christa Buechler

P577

2017-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28744589

http://www.w3.org/2001/XMLSchema#string